NEW YORK, Sept. 12, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds
investors that a securities class action has been filed against
Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO)
and certain of its officers, in the
United States District Court
Western District of Washington.
This class action has been expanded to include purchasers of Juno's
securities between May 9, 2016 and
July 7, 2016, inclusive (the "Class
Period").
This class action seeks to recover damages against Defendants
for alleged violations of the federal securities laws under the
Securities Exchange Act of 1934 (the "Exchange Act").
The complaint alleges that Defendants violated Sections 10(b),
14(e) and 20(a) of the Securities Exchange Act of 1934.
Juno is a biopharmaceutical company founded in 2013 that is
developing cell-based cancer immunotherapies. JCAR015 is its
leading product candidate, is currently in clinical trials.
The Complaint alleges that throughout the Class Period,
Defendants made materially false and misleading statements
regarding Juno's business, operational and compliance policies.
Particularly, Defendants made false and/or misleading statements
and/or partial disclosures regarding JCAR015's safety and made
public misrepresentations or failed to disclose material facts of
the death of patients in its Phase 2 clinical trial.
In May 2016, a patient in the
Phase 2 trial of JCAR015 died of a cerebral edema, a form of
neurotoxicity. Two additional patients in the ROCKET trial
died of cerebral edemas by early July, causing the FDA to issue a
clinical hold which forced Defendants to reveal the truth on
July 7, 2016, post-market.
Following this news, Juno's stock dropped $13.01 per share, or 31.87%, to close at
$27.81 on July
8, 2016.
No Class has yet been certified in the above action. To
discuss this action, or for any questions, please visit the firm's
site: http://www.bgandg.com/#!juno/c3onh or contact Peretz Bronstein, Esq. or his Investor Relations
Analyst, Yael Hurwitz of Bronstein,
Gewirtz & Grossman, LLC at 212-697-6484 or via email
info@bgandg.com. Those who inquire by e-mail are encouraged to
include their mailing address and telephone number. If you
suffered a loss in Juno, you have until September 12, 2016 to request that the Court
appoint you as lead plaintiff. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/deadline-alert--updated-class-period---bronstein-gewirtz--grossman-llc-reminds-shareholders-of-class-action-against-juno-therapeutics-inc-juno--lead-plaintiff-deadline-september-12-2016-300326033.html
SOURCE Bronstein, Gewirtz & Grossman, LLC